Retractable Technologies, Inc. (RTI)
RTI designs and manufactures safety medical devices featuring automated retraction technology, proven to effectively reduce the risk of needlestick injuries. Effective safety, a fact that is reflected not only by needlestick reduction data, but also by recognition from the health industry and non-profit reporting agencies. Our products feature automated retraction, allowing the needle to retract directly from the patient, effectively reducing exposure to the contaminated needle. Through innovation, education, and the development of safe and reliable medical devices, Retractable Technologies, Inc. strives to be a catalyst in reducing the worldwide spread of infectious disease.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
About us
Our vision is simple
CONTINUOUS INNOVATION AND DEVELOPMENT
Through innovation, education, and the development of safe and reliable medical devices, Retractable Technologies, Inc. strives to be a catalyst in reducing the worldwide spread of infectious disease.
Our Mission
Our mission is clear
SETTING THE STANDARD FOR EXCELLENCE
- To build a model corporation for employees, customers, community, and shareholders based on performance, pride, and profit;
- To set a standard for excellence, effectiveness, and integrity in selling and delivering our products; and
- To establish mutually beneficial relationships with other companies who share our overall vision.
Our History
Our history of innovation
STEADFAST IN ADVANCING HEALTHCARE SAFETY
In 1989, Retractable's founder, Thomas J. Shaw, saw a television news segment about a doctor who had contracted HIV from an accidental needlestick injury. The doctor complained that design engineers were insensitive and unresponsive to the dangers faced daily by frontline healthcare workers.
Shaw, a mechanical and structural engineer, was struck by the doctor's criticism and felt compelled to act. After spending a year developing preliminary design concepts, Shaw was awarded a grant by the National Institute on Drug Abuse, a subsidiary of the National Institutes of Health (NIH), to further develop his design concepts. Later he was awarded an additional grant to commercialize the production of one of his retractable syringe designs and to produce products for clinical trials.